# Relay Therapeutics (RLAY) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/RLAY
## Company Profile
- Ticker: RLAY
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Oncology
## Stock Data
- Close: 19.75 USD
- Market cap: 3421663212.3999996 USD
- Last updated: 2026-08-06
## Business Overview
### Structure-Based Precision Medicine
Relay Therapeutics develops small-molecule medicines using a platform designed to model protein motion and identify druggable conformations. Its clinical portfolio focuses on genetically defined cancers and diseases driven by difficult-to-target proteins.
### Zovegalisib in Breast Cancer
Zovegalisib is a mutant-selective PI3Kα inhibitor intended to preserve activity against oncogenic PIK3CA mutations while limiting inhibition of wild-type PI3Kα. It is being evaluated with fulvestrant in the Phase 3 ReDiscover-2 trial for previously treated HR-positive, HER2-negative advanced breast cancer.
### Frontline Combination Strategy
Relay selected zovegalisib with atirmociclib and endocrine therapy as its preferred triplet for first-line endocrine-sensitive metastatic breast cancer. The approach combines selective PI3Kα and CDK4 inhibition while Relay retains global rights to zovegalisib.
### Vascular Anomalies
Because activating PI3Kα mutations also drive many vascular anomalies, Relay is evaluating zovegalisib outside oncology. This program broadens the addressable population for the molecule and tests its mutant-selective profile in a genetic disease setting.
### NRAS Program
RLY-8161 is an NRAS-selective molecule in Phase 1/2 development for NRAS-mutant solid tumors. The program adds a second clinically tested precision-oncology mechanism to Relay’s pipeline.
## Why The Stock Is Moving

The latest monitored company update is “Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates.” The corresponding closing-price reaction is not yet available.

## Future Catalysts

- Initial zovegalisib clinical data in vascular anomalies expected at the ISSVA meeting.
- Initiation of a Phase 3 first-line breast-cancer trial of zovegalisib, atirmociclib and endocrine therapy expected in early 2027, subject to regulatory feedback.

## Recent News
- 2026-08-06 20:05 EST — [Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates](https://biopharmsignal.com/news/RLAY/relay-therapeutics-reports-second-quarter-2026-financial-results-and-corporate-u-f325a004) — Source: Relay Therapeutics
- 2026-07-30 20:05 EST — [Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026](https://biopharmsignal.com/news/RLAY/relay-therapeutics-to-announce-second-quarter-2026-financial-results-and-corpora-957fff80) — Source: Relay Therapeutics
- 2026-05-27 20:05 EST — [Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June](https://biopharmsignal.com/news/RLAY/relay-therapeutics-to-participate-in-two-upcoming-investor-conferences-in-june-9d492b03) — Source: Relay Therapeutics
- 2026-05-21 00:21 EST — [Relay Therapeutics Announces Pricing of Public Offering of Common Stock](https://biopharmsignal.com/news/RLAY/relay-therapeutics-announces-pricing-of-public-offering-of-common-stock-00372d13) — Source: Relay Therapeutics
- 2026-05-19 20:03 EST — [Relay Therapeutics Announces Proposed Public Offering of Common Stock](https://biopharmsignal.com/news/RLAY/relay-therapeutics-announces-proposed-public-offering-of-common-stock-858217e7) — Source: Relay Therapeutics